10-Q: Oragenics Reports Q2 2024 Results, Focuses on Brain Injury Drug Development

Oragenics, Inc. reported its financial results for the second quarter of 2024, highlighting a strategic shift towards developing its brain injury treatment, ONP-002, while managing financial constraints.

Summary

• Oragenics, Inc., a development-stage company, released its financial results for the quarter ended June 30, 2024.
• The company is now primarily focused on developing ONP-002 for mild traumatic brain injury (mTBI) treatment.
• Research and development activities for the nasal vaccine platform and lantibiotic program are currently inactive.
• The company reported a net loss of $2.3 million for the three months ended June 30, 2024, and $4.7 million for the six months ended June 30, 2024.
• Cash and cash equivalents decreased to $1.3 million as of June 30, 2024, from $3.4 million at the end of 2023.
• The company believes its current working capital will only be sufficient to meet business objectives through the fourth quarter of 2024.
• Oragenics secured approximately $3.2 million in gross proceeds from two public offerings of common stock during the six-month period ended June 30, 2024.
• The company has implemented cost-saving measures, including terminating its corporate office lease in Tampa, Florida.
• The company is seeking additional funding through various means, including sublicensing, joint ventures, and public or private financings.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress with its lead drug candidate and has secured some funding, the financial situation is precarious, with limited cash runway and ongoing losses. The legal dispute and NYSE non-compliance add to the negative sentiment.

Positives

• The company has successfully completed a Phase 1 clinical trial for ONP-002, demonstrating its safety and tolerability.
• Oragenics has secured patents for ONP-002 and its novel nasal delivery device, providing intellectual property protection.
• The company has a clear focus on developing ONP-002 for a significant unmet medical need, mild traumatic brain injury.
• The company has taken steps to reduce costs, including terminating its corporate office lease.
• The company has secured funding through the sale of approximately 2.6 million shares of its common stock in two public offerings.

Negatives

• The company has incurred significant net losses and negative cash flows since its inception.
• Oragenics' cash resources are expected to be sufficient only through the fourth quarter of 2024.
• The company has paused research and development activities for its nasal vaccine platform and lantibiotic program.
• The company is facing a legal dispute with Ladenburg Thalmann, which could negatively impact its financial position.
• The company received a notice from the NYSE American for non-compliance with continued listing standards due to low stockholders equity.

Risks

• The company's ability to continue operations depends on securing additional financing or achieving profitable operations.
• There is no assurance that additional financing will be available on acceptable terms or at all.
• Failure to obtain sufficient funding could require the company to curtail development programs and cut operating costs.
• The company is subject to the risk of delays in completing pre-clinical studies, clinical trials, or obtaining regulatory approvals.
• The company is involved in a legal dispute with Ladenburg Thalmann, which could have a material adverse effect on its business.
• The company is not in compliance with NYSE American continued listing standards and may be delisted if it does not regain compliance by October 18, 2025.
• The company's future success is heavily reliant on the successful development of ONP-002.

Future Outlook

The company expects to incur substantial expenditures to further develop its technologies and will require additional capital to continue operations after its current cash resources are exhausted. The company intends to seek additional funding through various means, including sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The company anticipates a Phase 2 clinical trial will be performed administering ONP-002 intranasally in concussed patients 2x a day for up to fourteen days. The Phase 2a feasibility study is expected to be performed in Australia with a target initiation date in the fourth quarter of 2024 to be followed closely by a Phase 2b proof of concept study in the US.

Management Comments

• The company is focused on the development of medical products that treat brain related illnesses and diseases.
• The company's lead product candidate is for the development, requisite clinical trials and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI or Concussion).
• The company will evaluate alternative opportunities for the nasal vaccine platform and lantibiotic programs moving forward.
• The company believes its working capital at June 30, 2024 will be sufficient to meet the business objectives as presently structured only through the fourth quarter of 2024.

Industry Context

The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 billion by 2027, indicating a significant market opportunity for Oragenics' ONP-002. The company's focus on intranasal drug delivery aligns with a growing trend in pharmaceutical development for more efficient and targeted drug administration.

Comparison to Industry Standards

• Oragenics' shift to focus on ONP-002 for mTBI aligns with the industry's increasing interest in neurological therapeutics, similar to companies like Biohaven Pharmaceuticals (now part of Pfizer) which developed Nurtec ODT for migraine.
• The company's use of a novel intranasal delivery device is comparable to companies like Impel NeuroPharma, which focuses on delivering drugs directly to the upper nasal cavity for neurological conditions.
• The reported net loss of $4.7 million for the six months ended June 30, 2024, is typical for a development-stage biotech company, but the limited cash runway is a concern compared to companies with more robust funding.
• The company's research and development expenses of $1.57 million for the six months ended June 30, 2024, are relatively low compared to larger biotech companies, reflecting its current financial constraints.
• The company's reliance on public offerings for funding is a common strategy for smaller biotech firms, but it also highlights the need for strategic partnerships or licensing deals to secure long-term financial stability.

Legal Proceedings

• The company is involved in a legal dispute with Ladenburg Thalmann, which is seeking $2.5 million in fees related to the Odyssey Health asset purchase.
• Oragenics initiated a confidential action for arbitration against Ladenburg with the Financial Industry Regulatory Authority (FINRA).
• Ladenburg filed a Complaint in federal court in the Southern District of Florida, seeking to move the venue from FINRA to the federal court in Miami-Dade County, which was denied.
• The company filed a motion to dismiss in the federal court action, which is currently pending.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings.
• Employees may be affected by cost-saving measures, including potential staff reductions.
• Customers and partners may be impacted by the company's strategic shift and focus on ONP-002.
• Creditors face increased risk due to the company's limited cash resources and ongoing losses.

Next Steps

• The company plans to apply for an Investigational New Drug application with the FDA.
• The company anticipates a Phase 2a clinical trial in Australia in the fourth quarter of 2024.
• The company plans a Phase 2b proof of concept study in the US following the Phase 2a study.
• The company will continue to seek additional funding through various means.

Key Dates

Keywords

ONP-002, mild traumatic brain injury, mTBI, concussion, nasal delivery, clinical trials, pharmaceutical, biotechnology, drug development, neurosteroids, brain injury, intranasal, capital raise, research and development